Heron Therapeutics (HRTX) Common Equity (2010 - 2026)

Heron Therapeutics (HRTX) has reported Common Equity for 17 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 125.34% year-over-year to $6.9 million; the trailing twelve-month figure through Jun 2026 stood at $6.9 million (up 125.34% YoY), and the FY2025 full-year result was $14.3 million, up 142.59% from the prior year.
• Common Equity declined to $6.9 million in Q2 2026 per HRTX's latest filing, from $9.1 million in the prior quarter.
• Across five years, Common Equity topped out at $24.0 million in Q1 2022 and bottomed at -$40.0 million in Q3 2024.
• Historically, Common Equity has averaged -$12.8 million across 5 years, with a median of -$24.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Common Equity plunged 350.32% in 2023, then surged 142.59% in 2025.
• Over 5 years, Common Equity stood at $13.6 million in 2022, then tumbled by 350.32% to -$34.0 million in 2023, then gained by 0.95% to -$33.7 million in 2024, then surged by 142.59% to $14.3 million in 2025, then slumped by 51.8% to $6.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $6.9 million, $9.1 million, and $14.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.